Want to track ATRC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
Zacks | 1 year ago
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
Zacks | 1 year ago
